ArticlePloS one2016
Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05047276 (Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma), which is not on this map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of AloCelyvir in Patients With Metastatic Uveal Melanoma
Who cites it
55 citing papers in PubMed, 72 citations in OpenAlex.
- Single-cell transcriptomic atlas of the human fetal uveal tract reveals heterogeneity in melanocyte populations.iScience · 2026Article
- Insights into inherited genetic variations and genetic ancestry of patients with high-risk melanoma.Melanoma research · 2026Article
- Ephrin Receptors and Ephrin Ligands in Uveal Melanoma: A Big Data Analysis Using Web Resources.International journal of molecular sciences · 2025Article
- Mapping the role of cytokine signaling at single-cell and structural resolution in uveal melanoma.Genes and immunity · 2025Article
- Genetic landscape of uveal melanoma in Southeast Asia: high 1q gains and unique patterns of metastasis risk.Eye and vision (London, England) · 2025Article
- Canonical and noncanonical NF-κB signaling in uveal melanoma: mechanisms, microenvironment, and therapeutic modulation.Medical hypothesis, discovery & innovation ophthalmology journal · 2025Review
- Single-cell and bulk transcriptome analysis reveals tumor cell heterogeneity and underlying molecular program in uveal melanoma.Journal of translational medicine · 2024Article
- The role of monoglyceride lipase gene in promoting proliferation, metastasis, and free fatty acid accumulation in uveal melanoma cells.Human cell · 2024Article
- Development of a prognostic risk model of uveal melanoma based on N7-methylguanosine-related regulators.Hereditas · 2024Article
- Review
- 1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature.Cell death discovery · 2024Article
- Single-cell RNA sequencing and AlphaFold 3 insights into cytokine signaling and its role in uveal melanoma.Frontiers in immunology · 2024Article
- PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma.Investigative ophthalmology & visual science · 2023Article
- Single-cell characterization of macrophages in uveal melanoma uncovers transcriptionally heterogeneous subsets conferring poor prognosis and aggressive behavior.Experimental & molecular medicine · 2023Article
- Increased Histological Tumor Pigmentation in Uveal Melanoma Is Related to Eye Color and Loss of Chromosome 3/BAP1.Ophthalmology science · 2023Article
- Article
- Microphthalmia-Associated Transcription Factor: A Differentiation Marker in Uveal Melanoma.International journal of molecular sciences · 2023Article
- Article
- TAP1, a potential immune-related prognosis biomarker with functional significance in uveal melanoma.BMC cancer · 2023Article
- Genetics and RNA Regulation of Uveal Melanoma.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionUveal melanoma (UM) with an inflammatory phenotype, characterized by infiltrating leukocytes and increased human leukocyte antigen (HLA) expression, carry an increased risk of death due to metastases. These tumors should be ideal for T-cell based therapies, yet it is not clear why prognostically-infaust tumors have a high HLA expression. We set out to determine whether the level of HLA molecules in UM is associated with other genetic factors, HLA transcriptional regulators, or microenvironmental factors.
methods28 enucleated UM were used to study HLA class I and II expression, and several regulators of HLA by immunohistochemistry, PCR microarray, qPCR and chromosome SNP-array. Fresh tumor samples of eight primary UM and four metastases were compared to their corresponding xenograft in SCID mice, using a PCR microarray and SNP array.
resultsIncreased expression levels of HLA class I and II showed no dosage effect of chromosome 6p, but, as expected, were associated with monosomy of chromosome 3. Increased HLA class I and II protein levels were positively associated with their gene expression and with raised levels of the peptide-loading gene TAP1, and HLA transcriptional regulators IRF1, IRF8, CIITA, and NLRC5, revealing a higher transcriptional activity in prognostically-bad tumors. Implantation of fresh human tumor samples into SCID mice led to a loss of infiltrating leukocytes, and to a decreased expression of HLA class I and II genes, and their regulators.
conclusionOur data provides evidence for a proper functioning HLA regulatory system in UM, offering a target for T-cell based therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.